2020 Q2 Form 10-Q Financial Statement
#000114036120017873 Filed on August 07, 2020
Income Statement
Concept | 2020 Q2 | 2019 Q4 | 2019 Q2 |
---|---|---|---|
Revenue | $38.76M | $0.00 | |
YoY Change | |||
Cost Of Revenue | $1.856M | ||
YoY Change | |||
Gross Profit | $36.90M | ||
YoY Change | |||
Gross Profit Margin | 95.21% | ||
Selling, General & Admin | $19.66M | $280.0K | |
YoY Change | |||
% of Gross Profit | 53.29% | ||
Research & Development | $6.694M | ||
YoY Change | |||
% of Gross Profit | 18.14% | ||
Depreciation & Amortization | |||
YoY Change | |||
% of Gross Profit | |||
Operating Expenses | $222.8K | $450.0K | $5.000K |
YoY Change | 4356.54% | ||
Operating Profit | $9.551M | -$5.000K | |
YoY Change | -191120.0% | ||
Interest Expense | $2.146M | $5.880M | |
YoY Change | |||
% of Operating Profit | 22.47% | ||
Other Income/Expense, Net | -$158.0K | ||
YoY Change | |||
Pretax Income | $9.393M | $4.800M | |
YoY Change | |||
Income Tax | $0.00 | ||
% Of Pretax Income | 0.0% | ||
Net Earnings | $9.393M | $3.630M | -$5.000K |
YoY Change | -187960.0% | ||
Net Earnings / Revenue | 24.24% | ||
Basic Earnings Per Share | |||
Diluted Earnings Per Share | $46.89K | $0.13 | |
COMMON SHARES | |||
Basic Shares Outstanding | |||
Diluted Shares Outstanding |
Balance Sheet
Concept | 2020 Q2 | 2019 Q4 | 2019 Q2 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $665.2K | $900.0K | |
YoY Change | |||
Cash & Equivalents | $12.81M | $4.968M | $0.00 |
Short-Term Investments | |||
Other Short-Term Assets | $146.6K | $300.0K | |
YoY Change | |||
Inventory | |||
Prepaid Expenses | $146.6K | $257.1K | |
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $811.8K | $1.152M | |
YoY Change | |||
LONG-TERM ASSETS | |||
Property, Plant & Equipment | |||
YoY Change | |||
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | $254.1M | $251.9M | |
YoY Change | |||
Other Assets | $300.0K | ||
YoY Change | |||
Total Long-Term Assets | $254.1M | $251.9M | |
YoY Change | |||
TOTAL ASSETS | |||
Total Short-Term Assets | $811.8K | $1.152M | |
Total Long-Term Assets | $254.1M | $251.9M | |
Total Assets | $254.9M | $253.1M | $300.0K |
YoY Change | 84860.85% | ||
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | |||
YoY Change | |||
Accrued Expenses | $437.5K | $96.90K | $200.0K |
YoY Change | 118.73% | ||
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $100.0K |
YoY Change | -100.0% | ||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $437.5K | $100.0K | $300.0K |
YoY Change | 45.82% | ||
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $8.750M | $22.00M | |
YoY Change | |||
Total Long-Term Liabilities | $8.750M | $22.00M | $0.00 |
YoY Change | |||
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $437.5K | $100.0K | $300.0K |
Total Long-Term Liabilities | $8.750M | $22.00M | $0.00 |
Total Liabilities | $9.187M | $8.847M | $300.0K |
YoY Change | 2962.49% | ||
SHAREHOLDERS EQUITY | |||
Retained Earnings | $3.083M | $1.618M | |
YoY Change | |||
Common Stock | |||
YoY Change | |||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $5.000M | $5.000M | $0.00 |
YoY Change | |||
Total Liabilities & Shareholders Equity | $254.9M | $253.1M | $300.0K |
YoY Change | 84860.85% |
Cashflow Statement
Concept | 2020 Q2 | 2019 Q4 | 2019 Q2 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | $9.393M | $3.630M | -$5.000K |
YoY Change | -187960.0% | ||
Depreciation, Depletion And Amortization | |||
YoY Change | |||
Cash From Operating Activities | -$129.8K | -$100.0K | -$10.00K |
YoY Change | 1197.5% | ||
INVESTING ACTIVITIES | |||
Capital Expenditures | |||
YoY Change | |||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $0.00 | ||
YoY Change | |||
Cash From Investing Activities | $0.00 | ||
YoY Change | |||
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 0.000 | 0.000 | 10.00K |
YoY Change | -100.0% | ||
NET CHANGE | |||
Cash From Operating Activities | -129.8K | -100.0K | -10.00K |
Cash From Investing Activities | 0.000 | ||
Cash From Financing Activities | 0.000 | 0.000 | 10.00K |
Net Change In Cash | -129.8K | -100.0K | 0.000 |
YoY Change | |||
FREE CASH FLOW | |||
Cash From Operating Activities | -$129.8K | -$100.0K | -$10.00K |
Capital Expenditures | |||
Free Cash Flow | |||
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2020Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
437458 | |
CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
96895 | |
CY2020Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1915793 | |
CY2019Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
3381091 | |
CY2019Q4 | us-gaap |
Assets
Assets
|
253076692 | |
CY2020Q2 | us-gaap |
Assets
Assets
|
254882553 | |
CY2020Q2 | us-gaap |
Assets Current
AssetsCurrent
|
811819 | |
CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
1151699 | |
CY2020Q2 | us-gaap |
Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
|
254070734 | |
CY2019Q4 | us-gaap |
Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
|
251924993 | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
0 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-229353 | ||
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
894589 | |
CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
0 | |
CY2019Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
0 | |
CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
665236 | |
CY2019Q4 | us-gaap |
Cash
Cash
|
894589 | |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
0 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
CY2020Q2 | us-gaap |
Cash
Cash
|
665236 | |
CY2019Q3 | us-gaap |
Cash
Cash
|
665236 | |
CY2020Q2 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
0 | |
CY2019Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
0 | |
CY2020Q2 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
250000 | |
CY2020Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; font-weight: bold;">Concentration of Credit Risk</div><div><br /></div><div style="text-align: justify;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</div></div> | ||
CY2020Q2 | us-gaap |
Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
|
1 | |
CY2019Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0 | |
CY2020Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.03 | |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.08 | ||
CY2020Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
932978 | |
us-gaap |
Gain Loss On Investments
GainLossOnInvestments
|
280726 | ||
CY2020Q2 | us-gaap |
Gain Loss On Investments
GainLossOnInvestments
|
-871960 | |
CY2019Q2 | us-gaap |
Gain Loss On Investments
GainLossOnInvestments
|
0 | |
us-gaap |
Gain Loss On Investments
GainLossOnInvestments
|
0 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
340563 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
0 | ||
us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-110527 | ||
us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
0 | ||
CY2019Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
0 | |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1865015 | ||
CY2020Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
254882553 | |
CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
253076692 | |
CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
8846895 | |
CY2020Q2 | us-gaap |
Liabilities
Liabilities
|
9187458 | |
us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div><font style="font-weight: bold;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</font></div><div><br /></div><div style="text-align: justify;">Silver Spike Acquisition Corp. (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on June 7, 2019. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (“Business Combination”).</div><div><br /></div><div style="text-align: justify;">Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends to focus on businesses in the cannabis industry that are compliant with all applicable laws and regulations within the jurisdictions in which they are located or operate and, in particular, the Company will not invest in, or consummate a Business Combination with, a target business that the Company determines has been operating, or whose business plan is to operate, in violation of U.S. federal laws, including the U.S. Controlled Substances Act. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</div><div><br /></div><div style="text-align: justify;">As of June 30, 2020, the Company had not commenced any operations. All activity through June 30, 2020 relates to the Company’s formation, the initial public offering (“Initial Public Offering”), which is described below, and, after the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.</div><div><br /></div><div style="text-align: justify;">The registration statement for the Company’s Initial Public Offering was declared effective on August 7, 2019. On August 12, 2019, the Company consummated the Initial Public Offering of 25,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units sold, the “Public Shares”) at $10.00 per unit, generating gross proceeds of $250,000,000, which is described in Note 3.</div><div><br /></div><div style="text-align: justify;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 7,000,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant in a private placement to Silver Spike Sponsor, LLC (the “Sponsor”), generating gross proceeds of $7,000,000, which is described in Note 4.</div><div><br /></div><div style="text-align: justify;">Transaction costs amounted to $14,413,362, consisting of $5,000,000 of underwriting fees, $8,750,000 of deferred underwriting fees and $663,362 of other offering costs. In addition, as of June 30, 2020, cash of $665,236 was held outside of the Trust and is available for working capital purposes.</div><div><br /></div><div style="text-align: justify;">Following the closing of the Initial Public Offering on August 12, 2019, an amount of $250,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of the Business Combination and (ii) the distribution of the funds in the Trust Account to the Company’s shareholders, as described below.</div><div><br /></div><div style="text-align: justify;">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. Nasdaq rules provide that the Business Combination must be with one or more target businesses that together have an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding any deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination.</div><div><br /></div><div style="text-align: justify;">The Company will provide its shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public shareholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account (initially $10.00 per share) as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The per-share amount to be distributed to shareholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 7). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.</div><div><br /></div><div style="text-align: justify;">The Company will proceed with a Business Combination only if the Company has net tangible assets, after payment of the deferred underwriting commission, of at least $5,000,001 upon such completion of a Business Combination and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company’s Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination and to waive its redemption rights with respect to any such shares in connection with a shareholder vote to approve a Business Combination or seek to sell any shares to the Company in a tender offer in connection with a Business Combination. Additionally, subject to the immediately succeeding paragraph, each public shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination.</div><div><br /></div><div style="text-align: justify;">If the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to 15% or more of the Public Shares without the Company’s prior written consent.</div><div><br /></div><div style="text-align: justify;">The Sponsor has agreed (a) to waive its redemption rights with respect to any Founder Shares and Public Shares held by it in connection with the completion of a Business Combination (and not seek to sell its shares to the Company in any tender offer the Company undertakes in connection with its initial Business Combination) and (b) not to propose an amendment to the Amended and Restated Certificate of Incorporation (i) to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares if the Company does not complete a Business Combination within 18 months from the closing of the Public Offering or (ii) with respect to any other provision relating to shareholders’ rights or pre-initial business combination activity, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment and (c) that the Founder Shares shall not participate in any liquidating distributions upon winding up if a Business Combination is not consummated. However, the Sponsor will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares purchased during or after the Initial Public Offering if the Company fails to complete its Business Combination.</div><div><br /></div><div style="text-align: justify;">The Company will have until February 12, 2021 (the “Combination Period”) to consummate a Business Combination. If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than 10 business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the Company’s board of directors, dissolve and liquidate, subject in each case to its obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. The underwriters have agreed to waive their rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).</div><div><br /></div><div style="text-align: justify;">The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a third party (other than the Company’s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent auditors), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</div></div> | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-5000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-229353 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
1465298 | ||
CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-161809 | |
CY2019Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5000 | |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
1627107 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-5000 | ||
CY2019Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-5000 | |
CY2020Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-219617 | |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-567577 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
5000 | ||
CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
20000 | |
CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
0 | |
CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5000004 | |
us-gaap |
Payments For Underwriting Expense
PaymentsForUnderwritingExpense
|
5000000 | ||
CY2020Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
222827 | |
us-gaap |
Operating Expenses
OperatingExpenses
|
680443 | ||
CY2019Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
5000 | |
CY2019Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-680443 | ||
CY2020Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-222827 | |
CY2019Q2 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
0 | |
CY2020Q2 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
61018 | |
us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
2145741 | ||
us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | ||
us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
63625 | ||
CY2019Q3 | us-gaap |
Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
|
250000000 | |
CY2020Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2020Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
CY2020Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2020Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
CY2020Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
CY2020Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
146583 | |
CY2019Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
257110 | |
us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
0 | ||
us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
68625 | ||
CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
1618159 | |
CY2020Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
3083457 | |
CY2019Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
25000 | |
CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5000007 | |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5000001 | |
us-gaap |
Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
|
2032875 | ||
CY2020Q2 | us-gaap |
Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
|
57808 | |
CY2019Q2 | us-gaap |
Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
|
0 | |
CY2020Q2 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
23683866 | |
CY2019Q4 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
239229796 | |
CY2020Q2 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
240695088 | |
CY2019Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
CY2020Q2 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
CY2019 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | |
us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; font-weight: bold;">Use of Estimates</div><div><br /></div><div style="text-align: justify;">The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period.</div><div><br /></div><div style="text-align: justify;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from those estimates.</div></div> | ||
CY2020Q2 | us-gaap |
Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
|
P5Y | |
CY2019Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
6250000 | |
CY2020Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
7544519 | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
7527169 | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2020-06-30 | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
NJ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
No | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
Silver Spike Acquisition Corp. | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001779474 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2020 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Shell Company
EntityShellCompany
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | ||
dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
sspk |
Underwriting Discount Fee Deferred
UnderwritingDiscountFeeDeferred
|
0.35 | ||
sspk |
Underwriting Fees Deferred
UnderwritingFeesDeferred
|
8750000 | ||
sspk |
Underwriting Discount Fee
UnderwritingDiscountFee
|
0.20 | ||
CY2020Q2 | sspk |
Deferred Underwriting Fee Payable Noncurrent
DeferredUnderwritingFeePayableNoncurrent
|
8750000 | |
CY2019Q4 | sspk |
Deferred Underwriting Fee Payable Noncurrent
DeferredUnderwritingFeePayableNoncurrent
|
8750000 | |
sspk |
Period To File Registration Statement
PeriodToFileRegistrationStatement
|
P15D | ||
sspk |
Period To Exercise Warrants After Business Combination
PeriodToExerciseWarrantsAfterBusinessCombination
|
P30D | ||
sspk |
Limitation Period To Transfer Assign Or Sell Warrants
LimitationPeriodToTransferAssignOrSellWarrants
|
P30D | ||
sspk |
Period To Exercise Warrants After Public Offerings
PeriodToExerciseWarrantsAfterPublicOfferings
|
P12M | ||
sspk |
Notice Period To Redeem Warrants
NoticePeriodToRedeemWarrants
|
P30D | ||
sspk |
Period For Registration Statement To Become Effective
PeriodForRegistrationStatementToBecomeEffective
|
P60D | ||
sspk |
Trading Days Threshold
TradingDaysThreshold
|
P30D | ||
sspk |
Number Of Trading Days
NumberOfTradingDays
|
P20D | ||
CY2020Q2 | sspk |
Class Of Warrant Or Right Redemption Price Of Warrants Or Rights
ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
|
0.01 | |
sspk |
Change In Value Of Ordinary Shares Subject To Possible Redemption
ChangeInValueOfOrdinarySharesSubjectToPossibleRedemption
|
-161812 | ||
sspk |
Change In Value Of Ordinary Shares Subject To Possible Redemption
ChangeInValueOfOrdinarySharesSubjectToPossibleRedemption
|
0 | ||
sspk |
Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
|
226656 | ||
sspk |
Offering Costs Paid Directly From Proceeds From Issuance Of Shares
OfferingCostsPaidDirectlyFromProceedsFromIssuanceOfShares
|
25000 | ||
sspk |
Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
|
0 | ||
sspk |
Offering Costs Paid Directly From Proceeds From Issuance Of Shares
OfferingCostsPaidDirectlyFromProceedsFromIssuanceOfShares
|
0 | ||
CY2020Q2 | sspk |
Stock Conversion Percentage Threshold
StockConversionPercentageThreshold
|
0.2 | |
CY2020Q1 | sspk |
Financial Instruments Subject To Mandatory Redemption Settlement Terms Equity Impact Of Changes In Fair Value Of Shares On Amount
FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsEquityImpactOfChangesInFairValueOfSharesOnAmount
|
-1627104 | |
CY2020Q2 | sspk |
Financial Instruments Subject To Mandatory Redemption Settlement Terms Equity Impact Of Changes In Fair Value Of Shares On Amount
FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsEquityImpactOfChangesInFairValueOfSharesOnAmount
|
161812 | |
sspk |
Transaction Costs
TransactionCosts
|
14413362 | ||
sspk |
Other Offering Costs
OtherOfferingCosts
|
663362 | ||
CY2019Q3 | sspk |
Redemption Price Per Share
RedemptionPricePerShare
|
10.00 | |
CY2020Q2 | sspk |
Interest Held To Pay Dissolution Expenses
InterestHeldToPayDissolutionExpenses
|
100000 |